2-(4-Chloro-benzylcarbamoyl)-6-(8-hydroxy-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-yl)-hexanoic acid benzyl ester | 1025909-10-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑二氮卓类
• 英文名称: 2-(4-Chloro-benzylcarbamoyl)-6-(8-hydroxy-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-yl)-hexanoic acid benzyl ester
• 英文别名: benzyl 2-[(4-chlorophenyl)methylcarbamoyl]-6-(8-hydroxy-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-3-yl)hexanoate
• CAS: 1025909-10-7
• 化学式: C₂₇H₃₀ClN₅O₄
• 分子量: 524.019
• InChiKey: XEUQARXFYUSFPY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  37
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  118
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  溶剂黄146 、 2-(4-Chloro-benzylcarbamoyl)-6-(8-hydroxy-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-yl)-hexanoic acid benzyl ester 在 sodium hydroxide 作用下， 以 1,4-二氧六环 为溶剂， 反应 16.0h， 生成
  参考文献：
  名称：

  AMP Deaminase Inhibitors. 4. Further N3-Substituted Coformycin Aglycon Analogues:  N3-Alkylmalonates as Ribose 5‘-Monophosphate Mimetics

  摘要：

  AMP deaminase (AMPDA) inhibitors increase the levels of extracellular adenosine and preserve intracellular adenylate pools in cellular models of ATP depletion and therefore represent a potential new class of antiischemic drugs. Recently we reported that replacement of the ribose 5'-monophosphate component of the very potent transition-state analogue AMPDA inhibitor coformycin monophosphate (1) with a simple alkylcarboxy group resulted in potent, selective, and cell-penetrating AMPDA inhibitors. Here we report that replacement of this alkylcarboxy group with an a-substituted alkylmalonic acid resulted in enhanced inhibitor potency. The lead compound, 3-(5,5-dicarboxy-6-(3-(trifluoromethyl)phenyl)-n-hexyl)coformation aglycon (21), exhibited an AMPDA K-i of 0.029 mu M which is (3 x 10(5))-fold lower than the K-M for the natural substrate AMP. A comparison of inhibitory potencies shows that the diacid analogues with cr-benzyl substituents are 2-10-fold more inhibitory than similar monoacid-monoester monoester-monoamide, or diester derivatives. Finally, these diacid analogues are 2-40-fold more potent inhibitors than the corresponding monocarboxylates.

  DOI：

  10.1021/jm9905413
• 作为产物：
  描述：

  tribenzyl methanetricarboxylate 在 sodium hydroxide 、 sodium tetrahydroborate 、 叠氮磷酸二苯酯 、 sodium hydride 、 三乙胺 、 sodium iodide 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 33.0h， 生成 2-(4-Chloro-benzylcarbamoyl)-6-(8-hydroxy-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-yl)-hexanoic acid benzyl ester
  参考文献：
  名称：

  AMP Deaminase Inhibitors. 4. Further N3-Substituted Coformycin Aglycon Analogues:  N3-Alkylmalonates as Ribose 5‘-Monophosphate Mimetics

  摘要：

  AMP deaminase (AMPDA) inhibitors increase the levels of extracellular adenosine and preserve intracellular adenylate pools in cellular models of ATP depletion and therefore represent a potential new class of antiischemic drugs. Recently we reported that replacement of the ribose 5'-monophosphate component of the very potent transition-state analogue AMPDA inhibitor coformycin monophosphate (1) with a simple alkylcarboxy group resulted in potent, selective, and cell-penetrating AMPDA inhibitors. Here we report that replacement of this alkylcarboxy group with an a-substituted alkylmalonic acid resulted in enhanced inhibitor potency. The lead compound, 3-(5,5-dicarboxy-6-(3-(trifluoromethyl)phenyl)-n-hexyl)coformation aglycon (21), exhibited an AMPDA K-i of 0.029 mu M which is (3 x 10(5))-fold lower than the K-M for the natural substrate AMP. A comparison of inhibitory potencies shows that the diacid analogues with cr-benzyl substituents are 2-10-fold more inhibitory than similar monoacid-monoester monoester-monoamide, or diester derivatives. Finally, these diacid analogues are 2-40-fold more potent inhibitors than the corresponding monocarboxylates.

  DOI：

  10.1021/jm9905413

文献信息

• AMP Deaminase Inhibitors. 4. Further N3-Substituted Coformycin Aglycon Analogues:  N3-Alkylmalonates as Ribose 5‘-Monophosphate Mimetics
  作者：Brett C. Bookser、Srinivas Rao Kasibhatla、Mark D. Erion

  DOI：10.1021/jm9905413

  日期：2000.4.1

  AMP deaminase (AMPDA) inhibitors increase the levels of extracellular adenosine and preserve intracellular adenylate pools in cellular models of ATP depletion and therefore represent a potential new class of antiischemic drugs. Recently we reported that replacement of the ribose 5'-monophosphate component of the very potent transition-state analogue AMPDA inhibitor coformycin monophosphate (1) with a simple alkylcarboxy group resulted in potent, selective, and cell-penetrating AMPDA inhibitors. Here we report that replacement of this alkylcarboxy group with an a-substituted alkylmalonic acid resulted in enhanced inhibitor potency. The lead compound, 3-(5,5-dicarboxy-6-(3-(trifluoromethyl)phenyl)-n-hexyl)coformation aglycon (21), exhibited an AMPDA K-i of 0.029 mu M which is (3 x 10(5))-fold lower than the K-M for the natural substrate AMP. A comparison of inhibitory potencies shows that the diacid analogues with cr-benzyl substituents are 2-10-fold more inhibitory than similar monoacid-monoester monoester-monoamide, or diester derivatives. Finally, these diacid analogues are 2-40-fold more potent inhibitors than the corresponding monocarboxylates.